Cysteamine Ophthalmic Solution Application Scope

Cystaran is a topical ophthalmic preparation of cysteamine, which reduces corneal cystine crystal accumulation by breaking disulfide bonds in cystine, forming soluble cysteine-cysteamine mixed disulfides that can exit the lysosome.

Indications:

Ocular cystinosis (corneal cystine crystal accumulation): Indicated for treatment of corneal cystine crystal deposits in patients with cystinosis.

Cysteamine Ophthalmic Solution Characteristics

Ingredients: Active ingredient: Cysteamine hydrochloride
Excipients: benzalkonium chloride, disodium edetate, sodium hydroxide, water for injection, etc.
Properties: Sterile, clear ophthalmic solution.
Packaging Specification: 0.44% solution in 15 mL dropper bottles.
Storage: Store in freezer at −25°C to −15°C before dispensing. After dispensing, store in refrigerator (2–8°C). Discard 1 week after opening.
Expiry Date: As indicated on package.
Executive Standard: FDA/EMA approved ophthalmic solution standard.
Approval Number: Per local regulatory agency.
Date of Revision: As indicated in insert.
Manufacturer: Sigma-Tau Pharmaceuticals, Inc. (Leadiant Biosciences).

Guidelines for the Use of Cystaran

Dosage and Administration:
- Recommended Dose: 1 drop in each eye, every waking hour.
- Administration: Ophthalmic use only. Do not ingest. Instill directly into the conjunctival sac.
- Missed Dose: Instill as soon as remembered; if close to next scheduled dose, continue with regular dosing.
Adverse Reactions:
- Common Adverse Reactions:
  - Ocular burning, stinging
  - Eye redness, irritation
  - Blurred vision
  - Photophobia, eye pain
- Serious Adverse Reactions:
  - Corneal ulceration (rare)
  - Severe hypersensitivity reactions
Contraindications: Hypersensitivity to cysteamine or formulation excipients.
Precautions:
- Strictly ophthalmic use only.
- Use with caution in patients with ocular surface disease.
- Must be kept refrigerated; discard after 1 week once opened.

Cysteamine Ophthalmic Solution Interactions

No major systemic drug interactions (topical use).
Avoid concurrent use with other ophthalmic preparations unless directed by physician.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.